Conclusion
The preponderance of evidence suggests a trend toward benefit from oral aloe vera use in reducing fasting blood glucose concentration and HbA1c. Triglyceride levels also seem to be reduced, although evidence regarding changes in LDL, HDL, and total cholesterol levels is conflicting. The weaknesses in study methods and inconsistency in data do not currently warrant recommendation of oral aloe vera for the management of diabetes mellitus or dyslipidemia.
The authors have declared no potential conflicts of interest.
Am J Health Syst Pharm. 2010;67(21):1804-1811. © 2010 American Society of Health-System Pharmacists, Inc.
All rights reserved. Posted with permission.
Comments